Pronto to Distribute Signal's Myeloma Test | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myeloma Health's parent company Signal Genetics said today that Pronto Diagnostics will distribute the Signal Myeloma Prognostic Risk Signature (MyPRS) test in Israel, under an exclusive agreement.

Tel Aviv-based Pronto provides molecular diagnostics-based oncology disease tests and genetic test kits, and it serves as a distributor for Pathwork Diagnostics and Epigenomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.